TMDX insider transaction filings
TransMedics Group, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-14. Screen TMDX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 5 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing by 1 insider — 1,336 shares, $109,058 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 7.
- Largest priced transaction: purchase of 1,336 shares @ $81.63 ($109,058) by Weill David, filed 2026-09-14.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Weill David — Director | 1 | 1 leg · 1,336 sh · $109,058 | — | — |
| Corcoran Nicholas — See remarks | 1 | — | — | 2 |
| Hassanein Waleed H — President & CEO, Director | 1 | — | — | 2 |
| Hernandez Gerardo — Chief Financial Officer | 1 | — | — | 2 |
| TOBIN JAMES R — Director | 1 | — | — | 1 |
Recent Form 4 filings — TransMedics Group, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-14 | 4 | Weill David — Director | Purchase (P): 1,336 @ $81.63 | EDGAR |
| 2026-08-17 | 4 | TOBIN JAMES R — Director | Gift (G): 18,000 @ $0 | EDGAR |
| 2026-07-14 | 4 | Corcoran Nicholas — See remarks | Grant/award (A): 11,727 @ $0 · Grant/award (A): 17,784 (derivative) @ $0 | EDGAR |
| 2026-07-14 | 4 | Hernandez Gerardo — Chief Financial Officer | Grant/award (A): 17,246 @ $0 · Grant/award (A): 26,153 (derivative) @ $0 | EDGAR |
| 2026-07-14 | 4 | Hassanein Waleed H — President & CEO, Director | Grant/award (A): 49,669 @ $0 · Grant/award (A): 112,984 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Gunderson Thomas J. — Director | Option exercise (M): 19,285 @ $2.21 · Sale (S): 9,624 @ $75.06 · Option exercise (M): 19,285 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Lovell Stephanie — Director | Grant/award (A): 2,922 @ $0 | EDGAR |
| 2026-05-22 | 4 | Weill David — Director | Grant/award (A): 2,922 @ $0 | EDGAR |
| 2026-05-22 | 4 | Basile Edward M — Director | Grant/award (A): 2,922 @ $0 | EDGAR |
| 2026-05-22 | 4 | Gunderson Thomas J. — Director | Grant/award (A): 2,922 @ $0 | EDGAR |
| 2026-05-22 | 4 | Kania Edwin — Director | Grant/award (A): 2,922 @ $0 | EDGAR |
| 2026-05-22 | 4 | TOBIN JAMES R — Director | Grant/award (A): 2,922 @ $0 | EDGAR |
| 2026-05-22 | 4 | RAINES MERILEE — Director | Grant/award (A): 2,922 @ $0 | EDGAR |
| 2026-05-21 | 4 | Forsyth Matthew S. — See Remarks | Grant/award (A): 15,409 @ $0 · Grant/award (A): 23,171 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Lovell Stephanie — Director | Sale (S): 1,193 @ $149.62 | EDGAR |
| 2026-03-06 | 4 | Weill David — Director | Option exercise (M): 3,571 @ $14.20 · Sale (S): 3,571 @ $146.82 · Option exercise (M): 3,571 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Hernandez Gerardo — Chief Financial Officer | Sale (S): 375 @ $139.12 · Option exercise (M): 1,324 @ $77.12 · Sale (S): 1,324 @ $147.21 · Option exercise (M): 5,912 @ $69.84 · Sale (S): 5,912 @ $147.21 · Option exercise (M): 1,324 (derivative) @ $0 · +1 more | EDGAR |
| 2026-03-04 | 4 | Ranganath Anil P. — See remarks | Sale (S): 864 @ $139.12 | EDGAR |
| 2026-03-04 | 4 | Corcoran Nicholas — See remarks | Tax withholding (F): 984 @ $135.30 · Sale (S): 2,966 @ $139.12 | EDGAR |
| 2026-02-20 | 4 | Cecere Giovanni — Chief Commercial Officer | Grant/award (A): 11,082 @ $0 · Grant/award (A): 16,734 (derivative) @ $0 | EDGAR |
| 2025-12-05 | 4 | Weill David — Director | Option exercise (M): 5,000 @ $14.20 · Sale (S): 5,000 @ $138.64 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-12-05 | 4 | Hernandez Gerardo — Chief Financial Officer | Sale (S): 920 @ $139.62 | EDGAR |
| 2025-11-26 | 4 | Ranganath Anil P. — See remarks | Option exercise (M): 3,000 @ $93.88 · Sale (S): 3,000 @ $145.22 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2025-11-18 | 4 | Hassanein Waleed H — President & CEO, Director | Purchase (P): 8,775 @ $114 | EDGAR |
| 2025-10-31 | 4 | Basile Edward M — Director | Option exercise (M): 4,142 @ $0.70 · Sale (S): 4,142 @ $130.45 · Option exercise (M): 4,142 (derivative) | EDGAR |
| 2025-08-08 | 4 | Hassanein Waleed H — President & CEO, Director | Purchase (P): 8,400 @ $118.68 · Purchase (P): 6,617 @ $116.08 · Purchase (P): 1,858 @ $116.85 | EDGAR |
| 2025-08-05 | 4 | Basile Edward M — Director | Option exercise (M): 4,143 @ $0.70 · Sale (S): 4,143 @ $125.51 · Option exercise (M): 4,143 (derivative) | EDGAR |
| 2025-06-10 | 4 | Ranganath Anil P. — See remarks | Sale (S): 686 @ $139.80 | EDGAR |
| 2025-05-29 | 4 | Basile Edward M — Director | Option exercise (M): 5,000 @ $0.70 · Sale (S): 5,000 @ $126.45 · Option exercise (M): 5,000 (derivative) | EDGAR |
| 2025-05-23 | 4 | Basile Edward M — Director | Grant/award (A): 2,134 @ $0 | EDGAR |
| 2025-05-23 | 4 | Lovell Stephanie — Director | Grant/award (A): 2,134 @ $0 | EDGAR |
| 2025-05-23 | 4 | Weill David — Director | Grant/award (A): 2,134 @ $0 · Sale (S): 732 @ $123.88 | EDGAR |
| 2025-05-23 | 4 | Gunderson Thomas James — Director | Grant/award (A): 2,134 @ $0 | EDGAR |
| 2025-05-23 | 4 | KANIA EDWIN M JR — Director | Grant/award (A): 2,134 @ $0 | EDGAR |
| 2025-05-23 | 4 | TOBIN JAMES R — Director | Grant/award (A): 2,134 @ $0 | EDGAR |
| 2025-05-23 | 4 | RAINES MERILEE — Director | Grant/award (A): 2,134 @ $0 | EDGAR |
| 2025-05-13 | 4 | Basile Edward M — Director | Option exercise (M): 6,000 @ $0.70 · Sale (S): 6,000 @ $115.63 · Option exercise (M): 6,000 (derivative) | EDGAR |
| 2025-03-05 | 4 | Khayal Tamer I — Chief Commercial Officer | Sale (S): 2,407 @ $76.43 | EDGAR |
| 2025-02-26 | 4 | Hernandez Gerardo — Chief Financial Officer | Grant/award (A): 3,521 @ $0 · Grant/award (A): 5,299 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Corcoran Nicholas — See Remarks | Grant/award (A): 12,676 @ $0 · Grant/award (A): 19,079 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Ranganath Anil P. — See remarks | Grant/award (A): 5,634 @ $0 · Grant/award (A): 8,479 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Hassanein Waleed H — President & CEO, Director | Grant/award (A): 59,781 @ $0 · Grant/award (A): 90,185 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Khayal Tamer I — Chief Commercial Officer | Grant/award (A): 17,606 @ $0 · Grant/award (A): 26,499 (derivative) @ $0 | EDGAR |
| 2025-01-10 | 4 | Khayal Tamer I — Chief Commercial Officer | Option exercise (M): 1,083 @ $13.28 · Sale (S): 1,083 @ $80.05 · Option exercise (M): 1,083 (derivative) @ $0 | EDGAR |
| 2024-12-11 | 4 | Hernandez Gerardo — Chief Financial Officer | Grant/award (A): 12,463 @ $0 · Grant/award (A): 18,922 (derivative) @ $0 | EDGAR |
| 2024-12-04 | 4 | Khayal Tamer I — Chief Commercial Officer | Option exercise (M): 1,084 @ $13.28 · Sale (S): 1,084 @ $86.40 · Option exercise (M): 1,084 (derivative) @ $0 | EDGAR |
| 2024-11-13 | 4 | Khayal Tamer I — Chief Commercial Officer | Option exercise (M): 1,458 @ $38.46 · Sale (S): 1,458 @ $90.04 · Option exercise (M): 1,458 (derivative) @ $0 | EDGAR |
| 2024-11-07 | 4 | Basile Edward M — Director | Option exercise (M): 6,750 @ $28.12 · Sale (S): 5,296 @ $83.35 · Sale (S): 1,454 @ $84.30 · Option exercise (M): 6,750 (derivative) @ $0 | EDGAR |
| 2024-11-05 | 4 | Khayal Tamer I — Chief Commercial Officer | Option exercise (M): 1,083 @ $13.28 · Sale (S): 1,083 @ $82.64 · Option exercise (M): 1,083 (derivative) @ $0 | EDGAR |
| 2024-10-17 | 4 | Hassanein Waleed H — President & CEO, Director | Option exercise (M): 8,625 @ $13.28 · Sale (S): 3,607 @ $131.91 · Sale (S): 3,518 @ $132.82 · Sale (S): 1,200 @ $134.23 · Sale (S): 300 @ $135.04 · Option exercise (M): 8,625 (derivative) @ $0 | EDGAR |
Recent 8-K events — TransMedics Group, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-21 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-27 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-24 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-01-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-06 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TMDX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →